Catch up with our insights on the big issues in pharma.
Our thought leadership library brings you our latest data-driven reports, infographics and articles that tackle the big issues, interesting niches and everything in between.
Global prescription drug sales are forecast to exceed $2 trillion by 2032, driven by a new era of obesity and autoimmune blockbusters, sustained M&A activity, and a dealmaking landscape that is shifting...
ASCO 2026 confirmed that oncology is entering a new phase, one defined less by whether new therapies work, and more by how to sequence them, who gets access, and what comes next.
Across hematology, breast canc...
Global prescription drug sales will exceed $2 trillion by 2032. Tirzepatide is on course to become the biggest-selling drug in history, cardiovascular and immunology are reshaping the therapy area rankings, a...
The 2026 Biomedtracker/Datamonitor Healthcare ASCO Weekend Update delivers independent expert analysis on the most consequential clinical trial data presented at ASCO annual meeting, covering key drugs...
ASCO 2026 data underscores a shift in how oncology assets are evaluated, with increasing focus on durability, tolerability, and real-world differentiation alongside efficacy.
These factors are becoming central to both commerci...
Antibody‑drug conjugates continue to draw sustained attention from dealmakers. The category combines clinical validation with ongoing technical flexibility, creating multiple paths to differentiation across...
